• Mashup Score: 0

    JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients

    Tweet Tweets with this article
    • Did you get a different perspective on @JELMYTO at #AUA23? If you didn't get a chance, you can still redefine possibilities by exploring the recently updated website: https://t.co/4gpgiRS1QO #Urology #Sponsored https://t.co/iNAy85QdZr

  • Mashup Score: 1

    JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients

    Tweet Tweets with this article
    • Grab a seat and lunch today at 12:30 PM CDT for @UroGenPharma’s #ProductTheater. @Dr_Jen_Linehan and Dr Sandip M Prasad share their experience with @JELMYTO and consider unique patient cases. Product Theater in The Square. https://t.co/NMvCdORzjJ #Sponsored #AUA23 https://t.co/8DDgdJ7nem

  • Mashup Score: 0

    JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients

    Tweet Tweets with this article
    • Join us at #AUA23 Friday 4/28 at 12:30 PM CDT for AN ADAPTABLE APPROACH: IS JELMYTO APPROPRIATE ACROSS PRESENTATIONS AND PRACTICE PATTERNS? Lunch and refreshments served! Product Theater in The Square. https://t.co/VdKHWlGCi1 #Urology #UroOncology #Sponsored https://t.co/qcJvVdp5dI

  • Mashup Score: 0

    JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients

    Tweet Tweets with this article
    • Don’t miss this #AUA23 Product Theater with @Dr_Jen_Linehan and Dr. Sandip M Prasad on @JELMYTO and unique patient cases. Lunch and refreshments served! Friday, April 28, 12:30 PM CDT. Product Theater in The Square. https://t.co/gsZTcAGDkv #UroOncology #Sponsored https://t.co/lFqzGotJie